NCT06104930Recruiting
Plasma Extracellular Vesicles in Meningioma Patients
Plasma Extracellular Vesicles in Meningioma Patients Following Radiotherapy as Liquid Biopsy
Source: ClinicalTrials.gov · Last updated 10 Mar 2026
Brief summary (registry, in English)
While surgical resection remains the primary treatment approach for symptomatic or growing meningiomas, radiotherapy represents an auspicious alternative in patients with meningiomas not safely amenable to surgery. Biopsies are often omitted in light of potential postoperative neurological deficits, resulting in a lack of histological grading and (molecular) risk stratification. In this prospective explorative biomarker study, extracellular vesicles in the bloodstream will be investigated in patients with macroscopic meningiomas to identify a biomarker for molecular risk stratification and disease monitoring.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 11 Oct 2023
- Start date
- 1 Nov 2023
- Primary completion date
- 1 Nov 2027
- Lead sponsor
- University Hospital Heidelberg
- NCT number
- NCT06104930
What you commit to
- Study type: Interventional
- Planned participants: 60
- From 1 Nov 2023 to the primary completion date, 1 Nov 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- previous or known tumor diseases \< 5 years ago
- previous (cerebral) radiotherapy
- simultaneous chemo/immunotherapy
Other
- evidence that the patient cannot adhere to the study protocol (e.g., non-compliance)
- the refusal of patients to participate in the study
- participation in another clinical study or observation period in a competing trial
Who the study is looking for
- confirmed meningioma (histologically or MRI/DOTATOC-PET CT)
- macroscopic tumor in MRI (either as definitive RT, or following subtotal resection or relapse)
- indication for radiotherapy
- completed wound healing after surgical intervention)
- Alter ≥ 18 Jahre
- Karnofsky Performance Score ≥ 60%
- written informed consent
- ability of subject to understand character and individual consequences of the trial
- adequate contraception for women of childbearing potential
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital of Heidelberg, Radiation Oncology Coordinator of this site? Confirm its status | Heidelberg | Germany | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.